Published in Hepatology on June 01, 2010
Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation. Crit Care (2011) 0.87
Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res (2014) 0.82
Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis. World J Gastroenterol (2015) 0.80
Portal hypertension as immune mediate disease. Hepat Mon (2014) 0.78
The Effect of Montelukast on Liver Damage in an Experimental Obstructive Jaundice Model. Viszeralmedizin (2015) 0.77
Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep (2014) 0.75
Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med (2010) 4.32
IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol (2006) 3.72
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 3.63
Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults. Gastroenterology (2013) 2.71
Role of Kupffer cells in host defense and liver disease. Liver Int (2006) 2.55
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2004) 2.45
International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev (2003) 2.25
TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut (2010) 2.24
Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res (2006) 2.13
Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion (2002) 2.09
IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol (2005) 2.05
Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut (2011) 2.01
Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis (2008) 1.96
Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol (2009) 1.96
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95
Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract (2007) 1.80
Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol (2009) 1.80
Expression and regulation of the chemokine CXCL16 in Crohn's disease and models of intestinal inflammation. Inflamm Bowel Dis (2010) 1.69
Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol (2009) 1.66
Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis (2008) 1.64
Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: implications for thrombus formation. Blood (2010) 1.61
Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes (2010) 1.58
Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion (2004) 1.57
Pathophysiology of acute experimental pancreatitis: lessons from genetically engineered animal models and new molecular approaches. Digestion (2005) 1.56
Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med (2004) 1.54
rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One (2007) 1.48
CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res (2005) 1.48
Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver Int (2008) 1.46
Atrial natriuretic peptide preconditioning protects against hepatic preservation injury by attenuating necrotic and apoptotic cell death. J Hepatol (2003) 1.45
Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity. J Urol (2013) 1.43
High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens (2004) 1.43
A new electrophysiological tool to investigate the spatial neuronal projections within the myenteric ascending reflex of the mouse colon. Clin Exp Pharmacol Physiol (2008) 1.39
The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology (2007) 1.31
The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med (2012) 1.31
SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun (2005) 1.29
Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol (2005) 1.27
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett (2010) 1.27
The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes (2012) 1.26
68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med (2010) 1.26
Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One (2010) 1.26
The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis (2005) 1.26
Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One (2012) 1.25
Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem (2006) 1.25
DUG is a novel homologue of translation initiation factor 4G that binds eIF4A. Biochem Biophys Res Commun (2002) 1.22
Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology (2002) 1.21
IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol (2007) 1.21
Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol (2010) 1.20
The role of interleukin-22 in hepatitis C virus infection. Cytokine (2008) 1.20
OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res (2008) 1.20
Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med (Berl) (2008) 1.19
The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population. Am J Gastroenterol (2007) 1.18
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2009) 1.18
Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol (2010) 1.18
Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun (2006) 1.17
Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab (2010) 1.17
Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging (2002) 1.16
Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn's disease. Inflamm Bowel Dis (2008) 1.16
Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling. BMC Genomics (2014) 1.16
Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat Rev Gastroenterol Hepatol (2009) 1.15
Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem (2008) 1.15
Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. Inflamm Bowel Dis (2006) 1.11
oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. Atherosclerosis (2009) 1.11
Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res (2005) 1.11
A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept (2006) 1.10
Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol (2007) 1.09
The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism (2006) 1.08
Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion. J Clin Endocrinol Metab (2009) 1.08
Glutathione protects the rat liver against reperfusion injury after prolonged warm ischemia. Ann Surg (2004) 1.08
Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. Am J Gastroenterol (2006) 1.08
Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol Ther (2011) 1.07
DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells. J Biol Chem (2004) 1.07
The impact of acute kidney injury in cirrhosis: does definition matter? Gut (2013) 1.07
Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. PLoS One (2010) 1.06
Risk of advanced colorectal neoplasia according to age and gender. PLoS One (2011) 1.05
Forward programming of pluripotent stem cells towards distinct cardiovascular cell types. Cardiovasc Res (2009) 1.05
Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer (2012) 1.04
SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res (2007) 1.04
Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology (2008) 1.03
The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept (2005) 1.02
Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide. Diabetes Care (2008) 1.02
Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes (2010) 1.02
Relative roles of the different Pax6 domains for pancreatic alpha cell development. BMC Dev Biol (2010) 1.02
Diabetes mellitus and gastric emptying: questions and issues in clinical practice. Diabetes Metab Res Rev (2009) 1.01
Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis. Am J Physiol Renal Physiol (2009) 1.01
Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. Scand J Gastroenterol (2006) 1.01
Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS One (2009) 1.01
Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery. Hum Gene Ther (2011) 1.01
A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol (2005) 1.00
Immune sensitization to yeast antigens in ASCA-positive patients with Crohn's disease. Inflamm Bowel Dis (2004) 1.00
Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab (2007) 1.00
Induction of cellular resistance against Kupffer cell-derived oxidant stress: a novel concept of hepatoprotection by ischemic preconditioning. Hepatology (2003) 1.00
Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease. Immunogenetics (2006) 1.00